FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034795132> ?p ?o ?g. }

• W2034795132 endingPage "1007" @default.
• W2034795132 startingPage "1002" @default.
• W2034795132 abstract "Background & AimsMultiple randomized controlled trials (RCTs) have been conducted to determine therapeutic efficacy of the biological agents for the inflammatory bowel diseases (IBD). However, the external validity of findings from RCTs might be compromised by their stringent selection criteria. We investigated the proportion of patients encountered during routine clinical practice who would qualify for enrollment into a pivotal RCT of biological agents for IBD.MethodsWe performed a retrospective cohort study of adult patients with moderate–severe IBD who presented to a tertiary referral center. Inclusion and exclusion criteria were extracted from published RCTs of biologics approved by the Food and Drug Administration and applied to the study population.ResultsOnly 31.1% of 206 patients with IBD (34% with Crohn's disease [CD], 26% with ulcerative colitis) would have been eligible to participate in any of the selected RCTs. Patients would have been excluded because they had stricturing or penetrating CD, took high doses of steroids, had comorbidities or prior exposure to biologics, or received topical therapies. Of the trial-ineligible patients with ulcerative colitis, 23.3% had colectomies, and 31.7% received infliximab, with a 63.2% response rate. Approximately half (49.4%) of the 82 trial-ineligible patients with CD received biological therapies, with lower response rates (60%) than trial-eligible patients (89%; P = .03).ConclusionsMost patients with moderate–severe IBD evaluated in an outpatient practice would not qualify for enrollment in a pivotal RCT of biological reagents; this finding raises important questions about their therapeutic efficacy beyond the clinical trial populations. Additional evaluation of the transparency of RCT design and selection criteria is needed to determine whether trial results can be generalized to the population. Multiple randomized controlled trials (RCTs) have been conducted to determine therapeutic efficacy of the biological agents for the inflammatory bowel diseases (IBD). However, the external validity of findings from RCTs might be compromised by their stringent selection criteria. We investigated the proportion of patients encountered during routine clinical practice who would qualify for enrollment into a pivotal RCT of biological agents for IBD. We performed a retrospective cohort study of adult patients with moderate–severe IBD who presented to a tertiary referral center. Inclusion and exclusion criteria were extracted from published RCTs of biologics approved by the Food and Drug Administration and applied to the study population. Only 31.1% of 206 patients with IBD (34% with Crohn's disease [CD], 26% with ulcerative colitis) would have been eligible to participate in any of the selected RCTs. Patients would have been excluded because they had stricturing or penetrating CD, took high doses of steroids, had comorbidities or prior exposure to biologics, or received topical therapies. Of the trial-ineligible patients with ulcerative colitis, 23.3% had colectomies, and 31.7% received infliximab, with a 63.2% response rate. Approximately half (49.4%) of the 82 trial-ineligible patients with CD received biological therapies, with lower response rates (60%) than trial-eligible patients (89%; P = .03). Most patients with moderate–severe IBD evaluated in an outpatient practice would not qualify for enrollment in a pivotal RCT of biological reagents; this finding raises important questions about their therapeutic efficacy beyond the clinical trial populations. Additional evaluation of the transparency of RCT design and selection criteria is needed to determine whether trial results can be generalized to the population." @default.
• W2034795132 created "2016-06-24" @default.
• W2034795132 creator A5038956446 @default.
• W2034795132 creator A5048657826 @default.
• W2034795132 creator A5070688316 @default.
• W2034795132 creator A5091551190 @default.
• W2034795132 date "2012-09-01" @default.
• W2034795132 modified "2023-10-10" @default.
• W2034795132 title "Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population" @default.
• W2034795132 cites W1625912164 @default.
• W2034795132 cites W1984426896 @default.
• W2034795132 cites W1991810959 @default.
• W2034795132 cites W2009025779 @default.
• W2034795132 cites W2015712245 @default.
• W2034795132 cites W2017295150 @default.
• W2034795132 cites W2022661087 @default.
• W2034795132 cites W2025211665 @default.
• W2034795132 cites W2035216610 @default.
• W2034795132 cites W2043990618 @default.
• W2034795132 cites W2048729604 @default.
• W2034795132 cites W2055211617 @default.
• W2034795132 cites W2063033401 @default.
• W2034795132 cites W2111570058 @default.
• W2034795132 cites W2111945961 @default.
• W2034795132 cites W2118422544 @default.
• W2034795132 cites W2126807394 @default.
• W2034795132 cites W2135094408 @default.
• W2034795132 cites W2136892596 @default.
• W2034795132 cites W2152026434 @default.
• W2034795132 cites W2152381563 @default.
• W2034795132 cites W2162766966 @default.
• W2034795132 cites W2166360124 @default.
• W2034795132 cites W2167806388 @default.
• W2034795132 cites W2171297959 @default.
• W2034795132 cites W2171341132 @default.
• W2034795132 cites W2615184173 @default.
• W2034795132 cites W4295333203 @default.
• W2034795132 doi "https://doi.org/10.1016/j.cgh.2012.02.004" @default.
• W2034795132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22343692" @default.
• W2034795132 hasPublicationYear "2012" @default.
• W2034795132 type Work @default.
• W2034795132 sameAs 2034795132 @default.
• W2034795132 citedByCount "231" @default.
• W2034795132 countsByYear W20347951322012 @default.
• W2034795132 countsByYear W20347951322013 @default.
• W2034795132 countsByYear W20347951322014 @default.
• W2034795132 countsByYear W20347951322015 @default.
• W2034795132 countsByYear W20347951322016 @default.
• W2034795132 countsByYear W20347951322017 @default.
• W2034795132 countsByYear W20347951322018 @default.
• W2034795132 countsByYear W20347951322019 @default.
• W2034795132 countsByYear W20347951322020 @default.
• W2034795132 countsByYear W20347951322021 @default.
• W2034795132 countsByYear W20347951322022 @default.
• W2034795132 countsByYear W20347951322023 @default.
• W2034795132 crossrefType "journal-article" @default.
• W2034795132 hasAuthorship W2034795132A5038956446 @default.
• W2034795132 hasAuthorship W2034795132A5048657826 @default.
• W2034795132 hasAuthorship W2034795132A5070688316 @default.
• W2034795132 hasAuthorship W2034795132A5091551190 @default.
• W2034795132 hasBestOaLocation W20347951321 @default.
• W2034795132 hasConcept C126322002 @default.
• W2034795132 hasConcept C168563851 @default.
• W2034795132 hasConcept C2777138892 @default.
• W2034795132 hasConcept C2778260677 @default.
• W2034795132 hasConcept C2779134260 @default.
• W2034795132 hasConcept C2779280984 @default.
• W2034795132 hasConcept C2780132546 @default.
• W2034795132 hasConcept C2780479503 @default.
• W2034795132 hasConcept C2908647359 @default.
• W2034795132 hasConcept C535046627 @default.
• W2034795132 hasConcept C71924100 @default.
• W2034795132 hasConcept C99454951 @default.
• W2034795132 hasConceptScore W2034795132C126322002 @default.
• W2034795132 hasConceptScore W2034795132C168563851 @default.
• W2034795132 hasConceptScore W2034795132C2777138892 @default.
• W2034795132 hasConceptScore W2034795132C2778260677 @default.
• W2034795132 hasConceptScore W2034795132C2779134260 @default.
• W2034795132 hasConceptScore W2034795132C2779280984 @default.
• W2034795132 hasConceptScore W2034795132C2780132546 @default.
• W2034795132 hasConceptScore W2034795132C2780479503 @default.
• W2034795132 hasConceptScore W2034795132C2908647359 @default.
• W2034795132 hasConceptScore W2034795132C535046627 @default.
• W2034795132 hasConceptScore W2034795132C71924100 @default.
• W2034795132 hasConceptScore W2034795132C99454951 @default.
• W2034795132 hasIssue "9" @default.
• W2034795132 hasLocation W20347951321 @default.
• W2034795132 hasLocation W20347951322 @default.
• W2034795132 hasOpenAccess W2034795132 @default.
• W2034795132 hasPrimaryLocation W20347951321 @default.
• W2034795132 hasRelatedWork W1708680437 @default.
• W2034795132 hasRelatedWork W2296926020 @default.
• W2034795132 hasRelatedWork W2321888678 @default.
• W2034795132 hasRelatedWork W2419464638 @default.
• W2034795132 hasRelatedWork W2617260208 @default.
• W2034795132 hasRelatedWork W2945945073 @default.
• W2034795132 hasRelatedWork W3022383156 @default.
• W2034795132 hasRelatedWork W3123012725 @default.

• next